Biosuis Entero

Farmaceutical form

Suspension for injection

The vaccine contains inactivated porcine rotavirus, serogroup A, selected serovars of inactivated enterotoxigenic E. coli strains, pathogenic for suckling piglets, containing F4ac, F5, F41 and F6 fimbria adhesins and also toxoid β (sensu lato) Clostridium perfringens, type C (produces a‑ and β₁‑, β₂‑toxin).

Composition

Each dose (2 ml) contains:

Active substances:

Porcine rotavirus, serogroup A, strain OSU 6, inactivated                            RP ≥ 1^*

Escherichia coli, serotype O149:K88 (F4ac), inactivated                               RP ≥ 1^*

Escherichia coli, serotype O101:K99 (F5 and F41), inactivated                    RP ≥ 1^* (F5), RP ≥ 1^* (F41)

Escherichia coli, serotype K85:987P (F6), inactivated                                     RP ≥ 1^*

Clostridium perfringens, type C, beta toxoid                                                    RP ≥ 1^{*, **}

F       = fimbrial adhesin

*       RP = Relative potency (ELISA), in comparison with reference serum obtained from vaccinated mice with vaccine batch, which complied in challenge test on target species.

**     minimal listed value complies with potency ≥ 20 IU required by Ph. Eur.

Adjuvant:

Montanide ISA 35 VG     0.52 ml

Target species

Pigs (pregnant gilts and sows)